Localization of heparin and low-molecular-weight heparin in the rat kidney

Summary

Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are cleared, at least in part, by the kidneys through a poorly understood process. This study was undertaken to explore the mechanism of renal clearance of these drugs. Rats were given fluorescein-5-isothiocyanate (FITC)-labeled UFH or LMWH intravenously. At intervals after injection, rats were euthanized and the kidneys were harvested and subjected to immunohistochemical analysis and fluorescence microscopy. Both UFH and LMWH were localized to renal tubular cells and no immunoperoxidase staining or fluorescence was detected in glomeruli. Autoradiography demonstrated similar intracellular distribution of radio-labeled UFH suggesting that this phenomenon is independent of the method used to label heparin. Fluoresence in the tubules increased as a function of time after UFH injection, but reached a plateau after LMWH injection suggesting that the rate of renal tubular uptake depends on the molecular size of the heparin. When administered prior to FITC-labeled UFH or LMWH, probenecid, a renal organic anion inhibitor, decreased the renal tubular uptake of the heparins, whereas cimetidine, a renal organic cation inhibitor, had no effect. These findings suggest that renal excretion of UFH and LMWH primarily reflects tubular uptake via an organic anion transport mechanism.

Keywords

Low-molecular-weight heparin - unfractionated heparin - renal clearance - renal tubular cells

• References

• 1 de Swart CAM, Nijmeyer B, Roelofs JMM. et al. Kinetics of intravenously administered heparin in normal humans. Blood 1982; 60: 1251-8.
• 2 Boneu B, Caranobe C, Cadroy Y. et al. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin Thromb Hemost 1988; 14: 18-27.
• 3 Barzu T, Molho P, Tobelem G. et al. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 1985; 845: 196-203.
• 4 Wells XE, Dawes J. Role of the liver and kidney in the desulphation of heparin in vivo. Thromb Haemost 1995; 74: 667-72.
• 5 Barzu T, Van Rijn JLMC, Petitou M. et al. Heparin degradation in the endothelial cells. Thromb Res 1987; 47: 601-9.
• 6 Fabian I, Bleiberg I, Aronson M. Increased uptake and desulphation of heparin by mouse macrophages in the presence of polycations. Biochim Biophys Acta 1978; 544: 69-76.
• 7 Caranobe C, Barret A, Gabaig AM. et al. Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY216) in normal and nephrectomized rabbits. Thromb Res 1985; 40: 129-33.
• 8 Palm M, Mattsson CH. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987; 58: 932-5.
• 9 Young E, Cosmi B, Weitz J. et al. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost 1993; 70: 625-30.
• 10 Young E, Wells P, Holloway S. et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71: 300-4.
• 11 Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98.
• 12 Levine M, Gent M, Hirsh J. et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81.
• 13 Koopman MMW, Prandoni P, Piovella F. et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-7.
• 14 Shum DKY, Baylis C, Scott JE. A micropuncture and renal clearance study in the rat of the urinary excretion of heparin, chondroitin sulphate and metabolic breakdown products of connective tissue proteoglycans. Clin Sci 1984; 67: 205-12.
• 15 Nagasawa K, Uchiyama H. Preparation and properties of biologically active fluorescent heparins. Biochim Biophys Acta 1978; 544: 430-40.
• 16 Malsch R, Guerrini M, Torri G. et al. Synthesis of a N’-alkylamine anticoagulant active low-molecular-mass heparin for radioactive and fluorescent labeling. Anal Biochem 1994; 217: 255-64.
• 17 Liaw PCY, Fredenburgh JC, Stafford AR. et al. Localization of the thrombin-binding domain on prothrombin fragment 2. J Biol Chem 1998; 273: 8932-9.
• 18 Somogyi A. Renal transport of drugs: specificity and molecular mechanisms. Clin Exp Pharmacol Physiol 1996; 23: 986-9.
• 19 Weiner IM, Roth L. Renal excretion of cimetidine. J Pharmacol Exp Ther 1981; 216: 516-20.
• 20 Beyer KJ, Russo HF, Tillson EK. et al. ‘Benemid’, p-(di-n-propylsulfamyl)-benzoic acid: its renal affinity and its elimination. Am J Physiol 1951; 166: 625-40.
• 21 de Miranda P, Good SS, Yarchoan R. et al. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDSrelated complex. Clin Pharmacol Ther 1989; 46: 494-500.
• 22 Lin JH, Chen IW, Deluna FA. et al. Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab Dispos 1992; 20: 608-13.
• 23 Foote EF, Halstenson CE. Effects of probenecid and cimetidine on renal disposition of ofloxacin in rats. Antimicrob Agents Chemother 1998; 42: 456-8.
• 24 Khorramian BA, Stivala SS. Small-angle X-ray scattering of high- and low-affinity heparin. Arch Biochem Biophys 1986; 247: 384-92.
• 25 Kanwar YS, Farquhar MG. Presence of heparan sulfate in the glomerular basement membrane. Proc Natl Acad Sci USA 1979; 76: 1303-7.
• 26 Sanchez G. Enhancement of heparin effect by probenecid. N Engl J Med 1975; 292: 48 (letter).
• 27 Sirak HD, McCleery RS, Artz CP. The effect of carinamide with heparin on the coagulation of human blood: a preliminary report. Surgery 1948; 24: 811.
• 28 Rodgers GM. Inappropriate use of enoxaparin in the treatment of deep-vein thrombosis. N Engl J Med 1999; 340: 62 (letter).
• 29 Rubin N, Lu S, Horn J. et al. The safety of low molecular weight heparin (LMWH) in renal failure: A case report of a large retroperitoneal hematoma as a complication of Lovenox use in a patient with renal failure. Blood 1998; 10: 125b (abstract).
• 30 Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to use of low-molecular-weight heparin?. Arch Intern Med 2002; 162: 2606-09.